North American Vaccine/Abbott Certiva
Labeling for DTaP vaccine states that it is recommended for four-dose schedule in diphtheria-tetanus-pertussis series, or to complete the series in children who have received one or two doses of whole-cell DTP vaccines. It is also recommended as the fifth dose in children who have received four whole-cell doses or three whole-cell doses followed by a dose of Certiva. "At this time, there are no data to establish the frequency of adverse events following a fifth dose of Certiva in children who previously received four doses of Certiva," labeling states. North American Vaccine is conducting a five-consecutive dose safety trial ("The Pink Sheet" Aug. 3, p. 3)
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth